Establishing safe high hydrostatic pressure devitalization thresholds for autologous head and neck cancer vaccination and reconstruction.
Journal
Cell death discovery
ISSN: 2058-7716
Titre abrégé: Cell Death Discov
Pays: United States
ID NLM: 101665035
Informations de publication
Date de publication:
23 Oct 2023
23 Oct 2023
Historique:
received:
06
03
2023
accepted:
03
10
2023
revised:
13
09
2023
medline:
24
10
2023
pubmed:
24
10
2023
entrez:
23
10
2023
Statut:
epublish
Résumé
High hydrostatic pressure specifically devitalizes cells and tissues without major changes in their molecular structure. Hence, high hydrostatic pressure may enhance the development of whole-cell anti-tumor vaccines, representing tumor heterogeneity and thus (neo-) antigen diversity. Moreover, safe devitalization of tumor-infiltrated supporting tissue may facilitate reimplantation for functional reconstruction. However, precise high hydrostatic pressure thresholds for safe cancer cell killing are unknown. Here, we show that high hydrostatic pressure of at least 450 MPa is necessary to safely devitalize head and neck squamous cell cancer. A pressure of 300 MPa, which has been used frequently in cancer vaccine preparation, resulted in partial devitalization with 27% live cells in flow cytometry and 4% remaining autofluorescence in cell culture after one week. The remaining cells could form vital tumors in the chorioallantoic membrane assay. In contrast, 450 MPa killed all cells in vitro and prevented tumor outgrowth in ovo. The effectiveness of 450 MPa was attributed to the induction of DNA double-strand breaks, independent of apoptosis, autophagy, or methuosis. Furthermore, 450 MPa continued to induce immunogenic cell death. Our results demonstrate that 450 MPa of high hydrostatic pressure induces safe and sustained devitalization of head and neck cancer cells and tissues. Because of the heterogeneity in pressure resistance, we propose our approach as a starting point for determining the precise thresholds for other cancer entities. Further studies on head and neck cancer should focus on immunological co-cultures, combinations of immune checkpoint inhibition, and accurate anatomical reconstruction with pressure-treated autografts.
Identifiants
pubmed: 37872173
doi: 10.1038/s41420-023-01671-z
pii: 10.1038/s41420-023-01671-z
pmc: PMC10593744
doi:
Types de publication
Journal Article
Langues
eng
Pagination
390Subventions
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : BA 3347/15-1
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : HA 7315/5-1
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : MA5799/2-2
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : BA 3347/15-1
Organisme : Deutsche Forschungsgemeinschaft (German Research Foundation)
ID : HA 7315/5-1
Informations de copyright
© 2023. Cell Death Differentiation Association (ADMC).
Références
Arch Otolaryngol Head Neck Surg. 2004 Apr;130(4):401-8
pubmed: 15096421
J Clin Oncol. 2006 Aug 1;24(22):3693-704
pubmed: 16832122
Ann Surg Oncol. 2016 May;23(5):1674-83
pubmed: 26714937
J Vis Exp. 2015 Oct 09;(104):
pubmed: 26484588
J Tissue Eng Regen Med. 2016 Oct;10(10):825-832
pubmed: 24403099
Int J Oncol. 2016 Mar;48(3):953-64
pubmed: 26718011
Cell Mol Biol (Noisy-le-grand). 2004 Jun;50(4):469-77
pubmed: 15529756
Ann N Y Acad Sci. 2010 Oct;1209:109-17
pubmed: 20958323
Anticancer Res. 2008 Nov-Dec;28(6B):3877-83
pubmed: 19192644
Front Oncol. 2019 Aug 28;9:805
pubmed: 31555582
Cells Tissues Organs. 2016;201(3):170-9
pubmed: 27002537
Sci Rep. 2016 Sep 27;6:33747
pubmed: 27671122
Isr Med Assoc J. 2000 Aug;2(8):615-20
pubmed: 10979358
Oncoimmunology. 2017 Aug 24;6(12):e1362528
pubmed: 29209567
Oncoimmunology. 2015 Jan 7;3(12):e968434
pubmed: 25964865
Radiat Oncol. 2012 Dec 21;7:219
pubmed: 23256610
Front Bioeng Biotechnol. 2021 Aug 12;9:730266
pubmed: 34458245
Cancers (Basel). 2022 May 18;14(10):
pubmed: 35626088
Anticancer Res. 2006 Jan-Feb;26(1A):85-9
pubmed: 16475683
Stem Cells Transl Med. 2017 Feb;6(2):677-687
pubmed: 28191770
PLoS One. 2015 Jul 30;10(7):e0133979
pubmed: 26226373
J Speech Lang Hear Res. 2006 Feb;49(1):194-208
pubmed: 16533084
Immunol Lett. 2017 Jul;187:27-34
pubmed: 28495513
Appl Microbiol Biotechnol. 2011 Mar;89(5):1305-14
pubmed: 21184058
Eur Arch Otorhinolaryngol. 2014 Feb;271(2):317-22
pubmed: 23818115
Urol Oncol. 2014 Jan;32(1):26.e17-24
pubmed: 23403205
J Immunotoxicol. 2010 Jul-Sep;7(3):194-204
pubmed: 20205624
Biomed Res Int. 2014;2014:379607
pubmed: 24877088
PLoS One. 2012;7(1):e30150
pubmed: 22291908
Cancer Immunol Immunother. 1993 May;36(5):300-6
pubmed: 8477416
Ann N Y Acad Sci. 2016 Nov;1383(1):139-159
pubmed: 27870078
Laryngoscope. 2011 Jan;121(1):106-10
pubmed: 21120838
Curr Med Chem. 2008;15(23):2329-36
pubmed: 18855663
Cancers (Basel). 2021 Feb 09;13(4):
pubmed: 33572437
Lancet. 2008 Dec 13;372(9655):2023-30
pubmed: 19022496
PLoS One. 2017 Nov 1;12(11):e0186958
pubmed: 29091921
JMIR Res Protoc. 2016 Aug 11;5(3):e162
pubmed: 27515295
Int J Cancer. 2014 Sep 1;135(5):1165-77
pubmed: 24500981
PLoS One. 2017 Feb 10;12(2):e0171539
pubmed: 28187172
Acta Otolaryngol Suppl. 2007 Feb;(557):66-72
pubmed: 17453449
Biotechnol Adv. 2010 Nov-Dec;28(6):659-72
pubmed: 20398747
Oncoimmunology. 2016 Nov 18;6(1):e1258505
pubmed: 28197379
Cell Tissue Bank. 2018 Sep;19(3):333-340
pubmed: 29264694
Curr Opin Otolaryngol Head Neck Surg. 2017 Apr;25(2):93-100
pubmed: 28059901